Details

Autor(en) / Beteiligte

• Bruden, Dana
• McMahon, Brian J
• Snowball, Mary
• Towshend-Bulson, Lisa
• Homan, Chriss
• Johnston, Janet M
• Simons, Brenna C
• Bruce, Michael G
• Cooley, Laura
• Spradling, Philip R
• Harris, Aaron M

Titel

Rate and durability of the clearance of HBsAg in Alaska Native persons with long-term HBV infection: 1982-2019

Ist Teil von

• Hepatology (Baltimore, Md.), 2023-11, Vol.79 (6), p.1412-1420

Ort / Verlag

United States

Erscheinungsjahr

2023

Link zum Volltext

Beschreibungen/Notizen

• A functional cure and therapeutic end point of chronic HBV infection is defined as the clearance of HBsAg from serum. Little is known about the long-term durability of HBsAg loss in the Alaskan Native population. We performed a retrospective cohort study of Alaska Native patients with chronic HBV-monoinfection from January 1982 through December 2019. The original group in this cohort was identified during a 1982 to 1987 population-based screening for 3 HBV serologic markers in 53,000 Alaska Native persons. With close to 32,000 years of follow-up, we assessed the frequency and duration of HBsAg seroclearance (HBsAg-negative for > 6 mo). We examined factors associated with HBsAg clearance and followed persons for a median of 13.1 years afterward to assess the durability of HBsAg clearance. Among 1079 persons with an average length of follow-up of 33 years, 260 (24%) cleared HBsAg at a constant rate of 0.82% per person/per year. Of the 260 persons who cleared, 249 (96%) remained HBsAg-negative, while 11 persons had ≥ 2 transient HBsAg-positive results in subsequent follow-up. Of the patients with chronic HBV monoinfection, 0.82% of people per year achieved a functional cure. HBsAg seroclearance was durable for treated and nontreated patients and lasted, on average, over 13 years without seroreversion.